ATE352306T1 - Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen - Google Patents

Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE352306T1
ATE352306T1 AT99937735T AT99937735T ATE352306T1 AT E352306 T1 ATE352306 T1 AT E352306T1 AT 99937735 T AT99937735 T AT 99937735T AT 99937735 T AT99937735 T AT 99937735T AT E352306 T1 ATE352306 T1 AT E352306T1
Authority
AT
Austria
Prior art keywords
uric acid
antioxidant
precursor
treatment
composition containing
Prior art date
Application number
AT99937735T
Other languages
English (en)
Inventor
Dyke Knox Van
Meir S Sacks
Original Assignee
Meir S Sacks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meir S Sacks filed Critical Meir S Sacks
Application granted granted Critical
Publication of ATE352306T1 publication Critical patent/ATE352306T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99937735T 1998-07-31 1999-08-02 Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen ATE352306T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12718498A 1998-07-31 1998-07-31

Publications (1)

Publication Number Publication Date
ATE352306T1 true ATE352306T1 (de) 2007-02-15

Family

ID=22428746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99937735T ATE352306T1 (de) 1998-07-31 1999-08-02 Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen

Country Status (9)

Country Link
EP (1) EP1100507B1 (de)
JP (1) JP2002521451A (de)
AT (1) ATE352306T1 (de)
AU (1) AU5250799A (de)
CA (1) CA2339004C (de)
DE (1) DE69934987T2 (de)
ES (1) ES2279627T3 (de)
IL (2) IL141160A0 (de)
WO (1) WO2000006171A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696485B1 (en) 1996-04-02 2004-02-24 Mars, Incorporated Procyanidin and cyclo-oxygenase modulator compositions
JP2003527418A (ja) * 2000-03-22 2003-09-16 マーズ インコーポレイテッド アセチルサリチル酸と併用したカカオプロシアニジンの抗血小板療法としての使用
CA2304869A1 (en) * 2000-04-07 2001-10-07 Roman Rozencwaig Method of medical treatment using uric acid or precursors thereof
FR2808192A1 (fr) * 2000-04-28 2001-11-02 Oreal Epichatechine comme inhibiteur de no-synthase et utilisations
US6479547B1 (en) * 2000-11-21 2002-11-12 Arthur Vanmoor Method of treating an infection by enhancing the effectiveness of the human immune system
ATE410177T1 (de) * 2001-02-09 2008-10-15 New Chapter Inc Zusammensetzung und verfahren zur rauchentgiftung
JP2002326922A (ja) * 2001-03-01 2002-11-15 Kose Corp 皮膚外用剤
ITVR20010031A1 (it) * 2001-03-12 2002-09-12 Hisanori Suzuki Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative.
WO2009047639A2 (en) * 2007-07-23 2009-04-16 Keimyung University Industry Academic Cooperation Foundation Epicatechin deficient green tea
KR101694482B1 (ko) * 2009-09-21 2017-01-10 (주)아모레퍼시픽 녹차의 줄기세포를 함유하는 항산화 및 항노화용 화장료 조성물
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
CN105497355A (zh) * 2015-07-23 2016-04-20 四川金堂海纳生物医药技术研究所 一种治疗破伤风的散剂药物及其制备方法
JP7333942B2 (ja) * 2019-06-07 2023-08-28 株式会社スタージェン 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法
CN114377124B (zh) * 2021-07-13 2023-08-25 中国医学科学院输血研究所 次黄嘌呤与注射用人免疫球蛋白的联合用药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (de) * 1982-09-16 1989-07-19 Hem Research, Inc. Wucherungshemmende Wirkung von ds-Ribonucleinsäuren auf Tumorzellen
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
US5043100A (en) * 1987-07-23 1991-08-27 Rutgers, The State University Of New Jersey Process for manufacture of natural antioxidant products from tea and spent tea
GB8918368D0 (en) * 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5391568A (en) * 1992-07-10 1995-02-21 American Health Foundation Inhibition of lung tumorigenesis by administration of a polyphenol
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
BR9602919A (pt) * 1996-06-27 1999-01-12 Cosmeticos Natural Ind Com Composições cosméticas para o cuidado da pele
AU4699299A (en) * 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Also Published As

Publication number Publication date
DE69934987T2 (de) 2007-05-16
AU5250799A (en) 2000-02-21
EP1100507B1 (de) 2007-01-24
EP1100507A4 (de) 2002-07-31
CA2339004C (en) 2008-04-01
DE69934987D1 (de) 2007-03-15
IL141160A (en) 2009-11-18
JP2002521451A (ja) 2002-07-16
EP1100507A1 (de) 2001-05-23
WO2000006171A1 (en) 2000-02-10
IL141160A0 (en) 2002-02-10
CA2339004A1 (en) 2000-02-10
ES2279627T3 (es) 2007-08-16

Similar Documents

Publication Publication Date Title
ATE352306T1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
BR0214772A (pt) sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas
Chang et al. Hyaluronan regulates PPARγ and inflammatory responses in IL-1β-stimulated human chondrosarcoma cells, a model for osteoarthritis
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60129943D1 (de) Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NZ292854A (en) Use of an photoactive compound to treat multiple sclerosis which is followed by light therapy
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE230394T1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69929810D1 (de) Verwendung von tetracyclinderivaten zur steigerung der interleukin-10 produktion
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
ATE113208T1 (de) Verwendung des wirkstoffs azelastin zur bekämpfung von psoriasis-erkrankungen.
EA200500849A1 (ru) Новые соединения лапахона и способы их применения
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE248592T1 (de) Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
Maiya et al. Photo-stimulatory effect of low energy helium-neon laser irradiation on excisional diabetic wound healing dynamics in Wistar rats
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
Kim et al. Cold Plasma Ameliorates Imiquimod‐Induced Psoriasis‐like Skin Inflammation in Mice

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties